诺和诺德减肥药丸获美国FDA批准，股价盘后大涨6%

Core Viewpoint - The FDA's approval of Novo Nordisk's oral weight loss pill positions the company to regain market share from Eli Lilly in the competitive landscape of effective oral weight loss medications [1][2] Group 1: Product Approval and Market Impact - The approved pill contains 25 mg of semaglutide, the same active ingredient found in injectable Wegovy and Ozempic, and will be marketed under the Wegovy brand name [1] - This approval may help Novo Nordisk recover from a challenging year marked by stock price declines, profit warnings, and competition from Eli Lilly [1] Group 2: Clinical Study Results - A 64-week late-stage study showed that participants taking the 25 mg oral semaglutide lost an average of 16.6% of their body weight, compared to a 2.7% weight loss in the placebo group [2] - The pill is approved for chronic weight management in adults who are obese or overweight with at least one related health condition, expanding the potential patient population amid rising healthcare costs associated with obesity [2] Group 3: Stock Market Reaction - Following the approval announcement, Novo Nordisk's stock rose by 6% in after-hours trading [2]